Chapter 65 and 72 Flashcards
Santamaria JAVMA 19
SQ infusion of carboplatin
Protocol not recommended
Marconato JAVMA 21
Timing of adjuvant chemo
tumor progression was longer in dogs that received chem <5 days than those who were >5days post op
timing of chemo is an important prognostic variable
Magidenko JAVMA22
Double limb amps
Most common indication: trauma
owners happy 17/18 cases
comps 3/18 with 2 needing revision
may be viable alternative
Hans VS 18
Effect of SSI on limb amp
Median DFI and MST did NOT differ between those with SSI and those without
Failure to complete chemo was associated with decreased DFI and survival
Billas VS 22
Risk factors for SSI after ampt
12.5% SSI
Factors that increased odds: bipolar sealing device, non-clean procedure, amp for infection or trauma
Gilliano VS 22
SQ VAP implantation
Jugulars had the most complications
Axillary and femoral were alternatives
Caraway JSAP 18
Tail avulsion in cats
All lost voluntary fxn, 8/15 urinary incant
Post op: 11 cats recovered motor/sn in 40 days and 5/9 recovered incontinence in 1 month
Giuffrida VS 18
HSA vs OSA
● 41 HAS, 29 tOSA
● Dogs with HSA were more likely to be: Male, have hindlimb tumors (78%, esp the tibia)
● Dogs with tOSA weighed 9.9kg more than HSA cases
● Most dogs had amp +/- chemo
o MST: 299d (10m) HSA
o MST 210d (7m) tOSA
● Both tumors were aggressive with a high rate of pulmonary mets
Selmic JAVMA 18
TPLO and OSA
● Dogs with a history of TPLO ≥ 1y prior were 40x more likely to develop proximal tibial OSA than dogs without TPLO
● Each 1 kg BW increase = 11% increase in odds of proximal tibial OSA
Nakano JAVMA 22
Cats OSA
● 46% overall distant metastatic rate
● osteosarcoma of the humerus was significantly associated with distant metastasis
● 10% local recurrence
● median survival time 527 days
Jones JAVMA 20
Rad features of benign vs malignant
● only 50% of benign infarcts and 40% of malignancy-associated infarcts were correctly classified
● 70% of benign lesions had medullary lysis (100% of malignant lesions did)
● radiology was not particularly helpful in distinguishing benign from malignancy-associated bone infarcts in dogs
Matsuyama JAVMA 18
cyclophosphamide chemo
● 19 dogs received carboplatin and MC chemotherapy, and 20 dogs received only carboplatin chemotherapy
● Median duration of MC chemotherapy for dogs in the carboplatin-MC group was 94 days (range, 7 to 586 days)
● treatment was discontinued for 11 (58%) dogs when cystitis developed. (consider prophylactic tx with furosemide)